National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pegfilgrastim
A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:Filgrastim SD-01
SD-01
SD-01 sustained duration G-CSF
US brand name:Neulasta
Abbreviation:GCSF-SD01



Previous:PEG-interferon alfa-2b, PEG-interleukin-2, PEG-Intron, pegaspargase, PEGASYS
Next:pegylated anti-GFR antibody fragment, pegylated granulocyte colony stimulating factor MAXY-G34, pegylated interferon alfa, pegylated irinotecan NKTR 102, pegylated liposomal doxorubicin hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov